Vabysmo is the first bispecific antibody for retinal disease, targeting both Ang-2 and BEGF-A to stablise blood vessels and reduce inflammation. Approved in over 100 countries, it treats wet AMD, diabetic macular edema, and RVO-related macular edema. Its latest innovation includes a newly approved prefilled syringe, enhancing clinical convenience.

BBH London